Tiotropium bromide

Small molecule

Approvedregulatory verdict

Evidence outlook

Approved: Asthma, Chronic Obstructive Pulmonary Disease

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Reliable signal

Also approved (2)
JP
  • Spiriva (tiotropium bromide hydrate), Nippon Boehringer Ingelheim: new bronchial asthma indication
Product first approved 2014pj.jiho.jp
EU
  • Spiriva Respimat: add-on maintenance bronchodilator treatment in adult patients with asthma who had one or more severe exacerbations in the previous year
Product first approved 2014medthority.com

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (73)
Asthma
NCT02066298 · Milton S. Hershey Medical Center
2014-07 – 2018-05 · Asthma
What this study did
NCT01634139 · Boehringer Ingelheim
2012-07 – 2015-12 · Asthma
What this study did
NCT01634152 · Boehringer Ingelheim
2012-07 – 2015-05 · Asthma
What this study did
NCT01257230 · Boehringer Ingelheim
2010-12 – 2013-12 · Asthma
What this study did
NCT01277523 · Boehringer Ingelheim
2011-01 – 2013-10 · Asthma
What this study did
NCT01290874 · Brigham and Women's Hospital
2011-03-30 – 2013-07 · Asthma
What this study did
NCT01316380 · Boehringer Ingelheim
2011-03 – 2012-04 · Asthma
What this study did
Chronic Obstructive Pulmonary Disease
NCT05161156 · Phargentis SA
2022-03-24 – 2022-11-29 · COPD
What this study did
NCT05927155 · Erasme University Hospital
2021-06-15 – 2022-03-30 · Pulmonary Disease, Chronic Obstructive
What this study did
NCT03745261 · Henan University of Traditional Chinese Medicine
2018-06-20 – 2020-06 · Pulmonary Disease, Chronic Obstructive
What this study did
NCT03137992 · Lupin, Inc.
2017-11-21 – 2018-04-30 · Chronic Obstructive Pulmonary Disease
What this study did
NCT02683668 · Imperial College London
2016-02-01 – 2018-01-01 · COPD, LUNG DISEASES, OBSTRUCTIVE
What this study did
NCT02796677 · AstraZeneca
2016-07-05 – 2017-06-08 · Chronic Obstructive Pulmonary Disease
What this study did
NCT01696058 · Boehringer Ingelheim
2012-09 – 2013-10 · Pulmonary Disease, Chronic Obstructive
What this study did
NCT01536262 · Boehringer Ingelheim
2012-02 – 2013-09 · Pulmonary Disease, Chronic Obstructive
What this study did
NCT01525615 · Boehringer Ingelheim
2012-02 – 2013-09 · Pulmonary Disease, Chronic Obstructive
What this study did
NCT01694771 · Boehringer Ingelheim
2012-09 – 2013-08 · Pulmonary Disease, Chronic Obstructive
What this study did
NCT01126437 · Boehringer Ingelheim
2010-05 – 2013-05 · Pulmonary Disease, Chronic Obstructive
What this study did
NCT01119937 · Novartis Pharmaceuticals
2010-05 – 2011-11 · Chronic Obstructive Pulmonary Disease
What this study did
NCT01012765 · Novartis Pharmaceuticals
2009-11 – 2011-01 · Chronic Obstructive Pulmonary Disease
What this study did
NCT00999908 · Novartis Pharmaceuticals
2009-10 – 2010-03 · Chronic Obstructive Pulmonary Disease
What this study did
NCT00662792 · Boehringer Ingelheim
2008-04-15 – 2009-07-22 · Pulmonary Disease, Chronic Obstructive
What this study did
NCT00673478 · Boehringer Ingelheim
2008-05 – 2009-06 · Pulmonary Disease, Chronic Obstructive
What this study did
NCT00387088 · Boehringer Ingelheim
2006-09 – 2009-01 · Pulmonary Disease, Chronic Obstructive
What this study did
NCT00668772 · Boehringer Ingelheim
2008-04-15 – 2008-11-21 · Pulmonary Disease, Chronic Obstructive
What this study did
NCT00662740 · Boehringer Ingelheim
2008-04-15 – 2008-11-21 · Pulmonary Disease, Chronic Obstructive
What this study did
NCT00144339 · Boehringer Ingelheim
2002-12 – 2008-02 · Pulmonary Disease, Chronic Obstructive
What this study did
NCT00308191 · Dey
2006-04 – 2006-12 · COPD
What this study did
NCT00157235 · Boehringer Ingelheim
2002-09 – 2006-04 · Pulmonary Disease, Chronic Obstructive
What this study did
NCT00168831 · Boehringer Ingelheim
2003-02 – 2005-06 · Pulmonary Disease, Chronic Obstructive
What this study did
NCT00168844 · Boehringer Ingelheim
2003-01 – 2005-06 · Pulmonary Disease, Chronic Obstructive
What this study did
NCT00277264 · Boehringer Ingelheim
2002-01 – 2004-05 · Pulmonary Disease, Chronic Obstructive
What this study did
NCT00239447 · Boehringer Ingelheim
2002-11-26 – 2004-04-29 · Pulmonary Disease, Chronic Obstructive
What this study did
NCT00274053 · Boehringer Ingelheim
2002-04 – 2004-04 · Pulmonary Disease, Chronic Obstructive
What this study did
NCT00239460 · Boehringer Ingelheim
2003-07 – 2004-03 · Pulmonary Disease, Chronic Obstructive
What this study did
NCT00239473 · Boehringer Ingelheim
2002-11 – 2003-12 · Pulmonary Disease, Chronic Obstructive
What this study did
NCT00240435 · Boehringer Ingelheim
2002-11 – 2003-12 · Pulmonary Disease, Chronic Obstructive
What this study did
NCT00274014 · Boehringer Ingelheim
2000-10 – 2003-10 · Pulmonary Disease, Chronic Obstructive
What this study did
Phase 2/3 (1)
Asthma
NCT03358147 · Pearl Therapeutics, Inc.
2017-12-13 – 2019-09-12 · Asthma
What this study did
Phase 2 (38)
Asthma
NCT04990167 · Nemours Children's Clinic
2022-01-01 – 2025-10-31 · Asthma in Children
What this study did
NCT01383499 · Boehringer Ingelheim
2011-08 – 2012-09 · Asthma
What this study did
NCT01122680 · Boehringer Ingelheim
2010-05 – 2011-04 · Asthma
What this study did
NCT00557700 · University Hospital, Ghent
2008-01 – 2010-05 · Asthma
What this study did
NCT00350207 · Boehringer Ingelheim
2006-07 – 2008-09 · Asthma
What this study did
NCT00365560 · Boehringer Ingelheim
2006-08 – 2007-11 · Asthma
What this study did
Chronic Obstructive Pulmonary Disease
NCT05838703 · Duke University
2023-05-01 – 2024-05-01 · Chronic Obstructive Pulmonary Disease (COPD)
What this study did
NCT04780984 · Nephron Pharmaceuticals Corporation
2020-11-01 – 2021-04-26 · Chronic Obstructive Pulmonary Disease (COPD)
What this study did
NCT03937479 · Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA
2019-05-01 – 2019-11-15 · COPD
What this study did
NCT03673670 · Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA
2018-07-16 – 2018-11-13 · COPD
What this study did
NCT03028142 · Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA
2017-01 – 2017-08 · Chronic Obstructive Pulmonary Disease Moderate
What this study did
NCT03118765 · Glenmark Specialty S.A.
2017-03-24 – 2017-07-31 · Mild to Moderate Chronic Obstructive Pulmonary Disease (COPD)
What this study did
NCT02203474 · Teva Branded Pharmaceutical Products R&D, Inc.
2014-08 – 2014-08 · Chronic Obstructive Pulmonary Disease, COPD
What this study did
NCT01222533 · Boehringer Ingelheim
2010-10 – 2011-11 · Pulmonary Disease, Chronic Obstructive
What this study did
NCT01040403 · Boehringer Ingelheim
2010-01 – 2011-02 · Pulmonary Disease, Chronic Obstructive
What this study did
NCT00528996 · Boehringer Ingelheim
2007-09-06 – 2009-05-05 · Pulmonary Disease, Chronic Obstructive
What this study did
NCT00720499 · Boehringer Ingelheim
2008-07 – 2009-02 · Pulmonary Disease, Chronic Obstructive
What this study did
NCT00696020 · Boehringer Ingelheim
2008-06 – 2009-02 · Pulmonary Disease, Chronic Obstructive
What this study did
NCT00535366 · Boehringer Ingelheim
2007-10 – 2008-09 · Pulmonary Disease, Chronic Obstructive
What this study did
NCT00515502 · GlaxoSmithKline
2007-06-21 – 2007-11-06 · Pulmonary Disease, Chronic Obstructive
What this study did
NCT00422604 · GlaxoSmithKline
2006-10 – 2007-05 · Pulmonary Disease, Chronic Obstructive
What this study did
NCT00292448 · Boehringer Ingelheim
2006-02 – 2007-03 · Pulmonary Disease, Chronic Obstructive
What this study did
NCT00128440 · Boehringer Ingelheim
2005-08 – 2006-09 · Pulmonary Disease, Chronic Obstructive
What this study did
NCT00325169 · GlaxoSmithKline
2005-12 – 2006-08 · Pulmonary Disease, Chronic Obstructive
What this study did
NCT00122434 · Boehringer Ingelheim
2005-07 – 2006-05 · Pulmonary Disease, Chronic Obstructive
What this study did
NCT02238119 · Boehringer Ingelheim
2002-02 – 2002-08 · Pulmonary Disease, Chronic Obstructive
What this study did
NCT02242240 · Boehringer Ingelheim
2001-03 – 2001-12 · Pulmonary Disease, Chronic Obstructive
What this study did
NCT02175342 · Boehringer Ingelheim
1998-03-01 – 1999-04-01 · Pulmonary Disease, Chronic Obstructive
What this study did
Other / comorbidity
NCT02586649 · James J. Peters Veterans Affairs Medical Center
2014-07 – 2019-12 · Spinal Cord Injury
What this study did
NCT01172925 · Hamilton Health Sciences Corporation
2010-11 – 2016-08 · NSCLC, Dyspnea
What this study did
NCT00737100 · Boehringer Ingelheim
2008-09 – 2010-04 · Cystic Fibrosis
What this study did
Phase 1/2 (1)
Chronic Obstructive Pulmonary Disease
NCT01785433 · Teva Branded Pharmaceutical Products R&D, Inc.
2013-01 – 2013-08 · COPD
What this study did
Phase 1 (34)
Chronic Obstructive Pulmonary Disease
NCT07267130 · Chia Tai Tianqing Pharmaceutical (Guangzhou) Co., Ltd.
2025-11-25 – 2026-08-21 · Chronic Obstructive Pulmonary Disease
What this study did
NCT06487416 · Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
2024-06-10 – 2024-10 · Chronic Obstructive Pulmonary Disease (COPD)
What this study did
NCT06326671 · Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
2024-02-28 – 2024-04 · Chronic Obstructive Pulmonary Disease
What this study did
NCT02969317 · Boehringer Ingelheim
2017-02-24 – 2017-06-15 · Pulmonary Disease, Chronic Obstructive
What this study did
NCT02573155 · AstraZeneca
2015-10 – 2016-08 · Asthma (Part 1), COPD (Part 2)
What this study did
NCT02441114 · Seoul National University Hospital
2015-07 – 2015-10 · Pulmonary Disease, Chronic Obstructive
What this study did
NCT01703845 · Boehringer Ingelheim
2012-10 – 2013-03 · Pulmonary Disease, Chronic Obstructive
What this study did
NCT00870896 · ThomasTruncale
2008-02 – 2012-06 · Chronic Obstructive Pulmonary Disease, Chronic Bronchitis
What this study did
NCT02231177 · Boehringer Ingelheim
2008-06 – 2008-11 · Pulmonary Disease, Chronic Obstructive
What this study did
NCT00555022 · GlaxoSmithKline
2007-12-12 – 2008-04-07 · Pulmonary Disease, Chronic Obstructive
What this study did
NCT00279019 · GlaxoSmithKline
2005-12-12 – 2006-06-13 · Pulmonary Disease, Chronic Obstructive
What this study did
Other / comorbidity
NCT05246046 · Orion Corporation, Orion Pharma
2022-02-16 – 2022-08-03 · Healthy Volunteers
What this study did
NCT04850144 · Orion Corporation, Orion Pharma
2021-04-26 – 2021-10-04 · Healthy Volunteers
What this study did
NCT03945344 · Orion Corporation, Orion Pharma
2019-05-27 – 2019-06-19 · Healthy Volunteer Study
What this study did
NCT03246581 · Kindeva Drug Delivery
2017-07-13 – 2018-05-03 · Healthy
What this study did
NCT03400241 · Orion Corporation, Orion Pharma
2018-02-19 – 2018-04-18 · Healthy Subjects
What this study did
NCT03155204 · Solventum US LLC
2017-04-25 – 2018-03-19 · Healthy
What this study did
NCT03302065 · Solventum US LLC
2016-05 – 2017-01 · Healthy
What this study did
NCT01355991 · James J. Peters Veterans Affairs Medical Center
2011-08 – 2016-08 · Spinal Cord Injury
What this study did
NCT02676297 · Solventum US LLC
2016-01 – 2016-07 · Healthy
What this study did
NCT02627625 · Solventum US LLC
2015-11 – 2016-06 · Healthy
What this study did
NCT02172534 · Boehringer Ingelheim
2006-09 – 2008-09 · Cystic Fibrosis
What this study did
NCT00257452 · Boehringer Ingelheim
2004-10 – 2005-07 · Healthy
What this study did
NCT02263976 · Boehringer Ingelheim
2003-08 – 2004-06 · Healthy
What this study did
NCT02172781 · Boehringer Ingelheim
2001-01 – 2001-04 · Healthy
What this study did
NCT02172417 · Boehringer Ingelheim
2000-07 – 2000-11 · Healthy
What this study did
NCT02177305 · Boehringer Ingelheim
1998-10 – 1998-12 · Healthy
What this study did
NCT02172339 · Boehringer Ingelheim
1998-04 – 1998-12 · Renal Insufficiency
What this study did
Phase 4 (77)
Asthma
NCT06679465 · University of Saskatchewan
2025-01-01 – 2027-01 · Asthma Bronchiale
What this study did
NCT05113615 · University of Saskatchewan
2021-12-13 – 2022-05-06 · Asthma
What this study did
NCT04648813 · University of Saskatchewan
2020-11-13 – 2021-04-20 · Allergic Asthma
What this study did
NCT03199976 · Helsinki University Central Hospital
2016-04-20 – 2020-11-18 · Wheezy Bronchitis, Asthmatic Bronchitis, Wheezing, Obstruction Airway
What this study did
NCT02039011 · University of Dundee
2014-02 – 2016-07 · Asthma
What this study did
NCT02622243 · University of Saskatchewan
2015-11 – 2016-03 · Asthma
What this study did
NCT00546234 · University of Alberta
2007-11 – 2014-01 · Asthma
What this study did
Chronic Obstructive Pulmonary Disease
NCT04061161 · University Medical Center Groningen
2019-08-19 – 2023-12-31 · COPD
What this study did
NCT04231214 · Fraunhofer-Institute of Toxicology and Experimental Medicine
2020-01-28 – 2023-04-18 · Chronic Obstructive Pulmonary Disease
What this study did
NCT03964207 · Boehringer Ingelheim
2019-11-25 – 2021-11-16 · Pulmonary Disease, Chronic Obstructive
What this study did
NCT02872090 · Centre Hospitalier Universitaire de Besancon
2016-03 – 2021-06-01 · Chronic Obstructive Pulmonary Disease
What this study did
NCT02546297 · Shanghai Pulmonary Hospital, Shanghai, China
2017-09-15 – 2021-03-01 · COPD, Bronchiectasis
What this study did
NCT03275116 · Maastricht University Medical Center
2017-07-07 – 2020-12 · Chronic Obstructive Airway Disease
What this study did
NCT04223843 · Boehringer Ingelheim
2020-01-08 – 2020-09-29 · Pulmonary Disease, Chronic Obstructive
What this study did
NCT03219866 · Wake Forest University Health Sciences
2017-10-03 – 2020-04-01 · COPD, COPD Exacerbation
What this study did
NCT04520230 · Tanta University
2014-10-31 – 2019-12-31 · COPD
What this study did
NCT03152149 · University of Dundee
2017-06-01 – 2019-11-26 · Chronic Obstructive Pulmonary Disease
What this study did
NCT02813200 · University Hospital, Bordeaux
2017-01-10 – 2019-03-08 · Chronic Obstructive Pulmonary Disease (COPD)
What this study did
NCT02567214 · Laval University
2016-06 – 2018-11-30 · COPD
What this study did
NCT02812862 · RWTH Aachen University
2016-08 – 2018-08 · COPD
What this study did
NCT03425617 · Queen's University
2017-01-01 – 2018-06-30 · Chronic Obstructive Pulmonary Disease
What this study did
NCT03055988 · Boehringer Ingelheim
2017-03-29 – 2018-03-26 · Pulmonary Disease, Chronic Obstructive
What this study did
NCT02988869 · Neutec Ar-Ge San ve Tic A.Ş
2016-08 – 2017-08 · COPD
What this study did
NCT02683109 · Boehringer Ingelheim
2016-03-08 – 2017-01-30 · Pulmonary Disease, Chronic Obstructive
What this study did
NCT01455129 · The First Affiliated Hospital of Guangzhou Medical University
2011-11 – 2016-08 · Chronic Obstructive Pulmonary Disease
What this study did
NCT01656005 · University of Dundee
2012-08 – 2016-07 · Chronic Obstructive Pulmonary Disease
What this study did
NCT02546349 · Taipei Veterans General Hospital, Taiwan
2014-07 – 2016-01 · COPD
What this study did
NCT01794780 · Novartis Pharmaceuticals
2013-02-05 – 2015-05-25 · COPD
What this study did
NCT02125734 · Novartis Pharmaceuticals
2014-04 – 2015-01 · Chronic Obstructive Pulmonary Disease, COPD
What this study did
NCT01466712 · KU Leuven
2011-11 – 2014-12 · COPD, Emphysema, Small Airway Disease
What this study did
NCT01959516 · Novartis Pharmaceuticals
2014-02 – 2014-10 · COPD
What this study did
NCT01663987 · Boehringer Ingelheim
2012-08-01 – 2014-05-01 · Pulmonary Disease, Chronic Obstructive
What this study did
NCT01662986 · Boehringer Ingelheim
2012-08-01 – 2014-04-01 · Pulmonary Disease, Chronic Obstructive
What this study did
NCT01922271 · Novartis Pharmaceuticals
2013-08 – 2014-01 · Chronic Obstructive Pulmonary Disease
What this study did
NCT01751113 · GlaxoSmithKline
2013-02 – 2013-11 · Pulmonary Disease, Chronic Obstructive
What this study did
NCT01693003 · Irmandade Santa Casa de Misericórdia de Porto Alegre
2013-03 – 2013-10 · Chronic Obstructive Pulmonary Disease
What this study did
NCT00975195 · Boehringer Ingelheim
2009-02 – 2013-07 · Pulmonary Disease, Chronic Obstructive
What this study did
NCT01397890 · AstraZeneca
2011-07 – 2013-06 · Chronic Obstructive Pulmonary Disease (COPD)
What this study did
NCT01644734 · Boehringer Ingelheim
2011-11 – 2013-03 · Pulmonary Disease, Chronic Obstructive
What this study did
NCT01483625 · Boehringer Ingelheim
2011-11 – 2012-12 · Pulmonary Disease, Chronic Obstructive
What this study did
NCT01072396 · Boehringer Ingelheim
2010-02 – 2011-11 · Pulmonary Disease, Chronic Obstructive
What this study did
NCT01307189 · Laval University
2005-04 – 2010-08 · Chronic Obstructive Pulmonary Disease
What this study did
NCT00523991 · Boehringer Ingelheim
2007-04 – 2010-07 · Pulmonary Disease, Chronic Obstructive
What this study did
NCT00525512 · Boehringer Ingelheim
2007-08 – 2010-06 · Pulmonary Disease, Chronic Obstructive, Exercise
What this study did
Early phase / not applicable (12)
Asthma
NCT04696965 · Chang Gung Memorial Hospital
2021-03-04 – 2023-11-20 · Asthma
What this study did
NCT00706446 · Brigham and Women's Hospital
2008-06 – 2011-09 · Asthma
What this study did
Chronic Obstructive Pulmonary Disease
NCT07541378 · Medical University of Bialystok
2024-03-11 – 2027-09-01 · COPD (Chronic Obstructive Pulmonary Disease)
What this study did
NCT03842839 · Guangzhou Institute of Respiratory Disease
2019-08-01 – 2025-05-07 · Airway Remodeling, Chronic Obstructive Pulmonary Disease
What this study did
NCT05295355 · Guangzhou Institute of Respiratory Disease
2021-01-25 – 2025-03 · Chronic Obstructive Pulmonary Disease
What this study did
NCT04994574 · Yonsei University
2021-08-23 – 2024-07-25 · Chronic Obstructive Pulmonary Disease
What this study did
NCT04999930 · National University of Malaysia
2020-01-10 – 2021-02-28 · Chronic Obstructive Pulmonary Disease
What this study did
NCT03504527 · Huashan Hospital
2018-05-01 – 2019-05-01 · Asthma-COPD Overlap
What this study did
NCT03258749 · Huashan Hospital
2017-11-01 – 2018-10-31 · Chronic Obstructive Pulmonary Disease
What this study did
NCT02331940 · University of Crete
2010-03 – 2014-09 · Chronic Obstructive Pulmonary Disease
What this study did
NCT00981851 · Radboud University Medical Center
2009-09 – 2011-05 · Chronic Obstructive Pulmonary Disease, Cardiovascular Disease, Smoking, Bronchodilation
What this study did
Other / comorbidity
NCT04137029 · Federal State Budgetary Institution, Pulmonology Scientific Research Institute
2019-04-24 – 2020-10 · Health, Subjective, Hyperreactivity, Bronchial
What this study did
Used as active comparator (81)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (44)
Asthma
NCT03158311 · Novartis Pharmaceuticals
2018-02-05 – 2019-07-19 · Asthma
What this study did
NCT02676089 · Chiesi Farmaceutici S.p.A.
2016-04-06 – 2018-05-28 · Asthma
What this study did
Chronic Obstructive Pulmonary Disease
NCT03095456 · Mylan Inc.
2017-03-27 – 2017-11-25 · Chronic Obstructive Pulmonary Disease, COPD, Low Peak Inspiratory Flow Rate (PIFR)
What this study did
NCT02518139 · Mylan Inc.
2015-09 – 2017-06 · Chronic Obstructive Pulmonary Disease (COPD)
What this study did
NCT01837927 · Novartis Pharmaceuticals
2014-04 – 2016-04 · Pulmonary Disease, Chronic Obstructive
What this study did
NCT01911364 · Chiesi Farmaceutici S.p.A.
2014-01 – 2016-03 · Chronic Obstructive Pulmonary Disease
What this study did
NCT02276222 · Sunovion Respiratory Development Inc.
2014-10 – 2016-02 · Chronic Obstructive Pulmonary Disease (COPD)
What this study did
NCT02207829 · GlaxoSmithKline
2014-09-01 – 2015-06-15 · Pulmonary Disease, Chronic Obstructive
What this study did
NCT02257385 · GlaxoSmithKline
2014-10-15 – 2015-05-04 · Pulmonary Disease, Chronic Obstructive
What this study did
NCT01970878 · Pearl Therapeutics, Inc.
2013-11 – 2015-03 · Chronic Obstructive Pulmonary Disease (COPD)
What this study did
NCT01854645 · Pearl Therapeutics, Inc.
2013-05 – 2015-02 · Chronic Obstructive Pulmonary Disease
What this study did
NCT01964352 · Boehringer Ingelheim
2013-11 – 2014-11 · Pulmonary Disease, Chronic Obstructive
What this study did
NCT02006732 · Boehringer Ingelheim
2013-11 – 2014-11 · Pulmonary Disease, Chronic Obstructive
What this study did
NCT01513460 · Novartis Pharmaceuticals
2012-04 – 2013-12 · Chronic Obstructive Pulmonary Disease
What this study did
NCT01431287 · Boehringer Ingelheim
2011-09 – 2013-11 · Pulmonary Disease, Chronic Obstructive
What this study did
NCT01533935 · Boehringer Ingelheim
2012-02 – 2013-11 · Pulmonary Disease, Chronic Obstructive
What this study did
NCT01533922 · Boehringer Ingelheim
2012-03 – 2013-11 · Pulmonary Disease, Chronic Obstructive
What this study did
NCT01431274 · Boehringer Ingelheim
2011-09 – 2013-09 · Pulmonary Disease, Chronic Obstructive
What this study did
NCT01559116 · Boehringer Ingelheim
2012-03 – 2013-08 · Pulmonary Disease, Chronic Obstructive
What this study did
NCT01574651 · Novartis Pharmaceuticals
2012-05 – 2013-04 · Chronic Obstructive Pulmonary Disease (COPD)
What this study did
NCT01613326 · Novartis Pharmaceuticals
2012-06 – 2013-01 · Chronic Obstructive Pulmonary Disease
What this study did
NCT01285492 · Novartis Pharmaceuticals
2011-01 – 2012-09 · Chronic Obstructive Pulmonary Disease (COPD)
What this study did
NCT01395888 · GlaxoSmithKline
2011-06-30 – 2012-08-06 · Pulmonary Disease, Chronic Obstructive
What this study did
NCT01490125 · Novartis Pharmaceuticals
2011-10 – 2012-08 · Chronic Obstructive Pulmonary Disease
What this study did
NCT00845728 · Novartis Pharmaceuticals
2009-03 – 2012-07 · Chronic Obstructive Pulmonary Disease
What this study did
NCT01120691 · Novartis Pharmaceuticals
2010-04 – 2012-07 · Chronic Obstructive Pulmonary Disease
What this study did
NCT01316900 · GlaxoSmithKline
2011-03-01 – 2012-04-24 · Pulmonary Disease, Chronic Obstructive
What this study did
NCT01316913 · GlaxoSmithKline
2011-03 – 2012-04 · Pulmonary Disease, Chronic Obstructive
What this study did
NCT01202188 · Novartis Pharmaceuticals
2010-09 – 2012-03 · Chronic Obstructive Pulmonary Disease (COPD)
What this study did
NCT01294787 · Novartis Pharmaceuticals
2011-02 – 2011-11 · COPD
What this study did
NCT00929110 · Novartis
2009-06 – 2011-04 · Chronic Obstructive Pulmonary Disease
What this study did
NCT01040689 · Boehringer Ingelheim
2010-01 – 2011-01 · Pulmonary Disease, Chronic Obstructive
What this study did
NCT00900731 · Novartis Pharmaceuticals
2009-06 – 2010-03 · Chronic Obstructive Pulmonary Disease
What this study did
NCT00435760 · AstraZeneca
2007-02 – 2007-08 · Chronic Obstructive Pulmonary Disease (COPD)
What this study did
Phase 2/3 (1)
Chronic Obstructive Pulmonary Disease
NCT00463567 · Novartis
2007-04 – 2008-08 · Pulmonary Disease, Chronic Obstructive, COPD, Lung Diseases, Obstructive
What this study did
Phase 2 (16)
Asthma
NCT02382510 · Theron Pharmaceuticals, Inc.
2015-04 – 2016-03 · Asthma
What this study did
Chronic Obstructive Pulmonary Disease
NCT03084796 · Chiesi Farmaceutici S.p.A.
2017-07-28 – 2018-06-06 · COPD, Chronic Obstructive Pulmonary Disease
What this study did
NCT01708057 · AstraZeneca
2012-10 – 2012-12 · Chronic Obstructive Pulmonary Disease, COPD
What this study did
NCT01498081 · AstraZeneca
2012-03 – 2012-10 · COPD
What this study did
NCT01587079 · Pearl Therapeutics, Inc.
2012-04 – 2012-10 · Chronic Obstructive Pulmonary Disease
What this study did
NCT01566773 · Pearl Therapeutics, Inc.
2012-03 – 2012-08 · Chronic Obstructive Pulmonary Disease
What this study did
NCT01426009 · Sunovion Respiratory Development Inc.
2011-08 – 2011-12 · Chronic Obstructive Pulmonary Disease
What this study did
NCT01068613 · Novartis Pharmaceuticals
2010-01 – 2010-08 · Chronic Obstructive Pulmonary Disease
What this study did
NCT00950807 · GlaxoSmithKline
2009-09-01 – 2010-03-15 · Pulmonary Disease, Chronic Obstructive
What this study did
NCT00939211 · AstraZeneca
2009-06 – 2009-11 · Chronic Obstructive Pulmonary Disease
What this study did
NCT00868231 · AstraZeneca
2009-03 – 2009-07 · Chronic Obstructive Pulmonary Disease (COPD)
What this study did
NCT00501852 · Novartis Pharmaceuticals
2007-07 – 2007-12 · Chronic Obstructive Pulmonary Disease
What this study did
NCT02242279 · Boehringer Ingelheim
2004-06 – 2004-12 · Pulmonary Disease, Chronic Obstructive
What this study did
Phase 1/2 (2)
Chronic Obstructive Pulmonary Disease
NCT01176903 · Chiesi Farmaceutici S.p.A.
2010-08 – 2011-08 · Chronic Obstructive Pulmonary Disease (COPD)
What this study did
NCT00871182 · Pearl Therapeutics, Inc.
2009-03 – 2009-09 · Chronic Obstructive Pulmonary Disease
What this study did
Phase 1 (3)
Chronic Obstructive Pulmonary Disease
NCT02059434 · AstraZeneca
2013-09-01 – 2014-10-06 · Chronic Obstructive Pulmonary Disease (COPD), Asthma
What this study did
NCT00532350 · Novartis
2007-07 – 2008-01 · Chronic Obstructive Pulmonary Disease
What this study did
Other / comorbidity
NCT03097380 · AstraZeneca
2017-04-26 – 2017-12-30 · Healthy Volunteers
What this study did
Phase 4 (15)
Chronic Obstructive Pulmonary Disease
NCT06282861 · Fundacio Privada Mon Clinic Barcelona
2024-02-29 – 2025-01-23 · Chronic Obstructive Pulmonary Disease
What this study did
NCT05165485 · Theravance Biopharma
2022-01-07 – 2023-11-20 · Chronic Obstructive Pulmonary Disease
What this study did
NCT02603393 · Novartis Pharmaceuticals
2015-11-20 – 2017-07-18 · Chronic Obstructive Pulmonary Disease (COPD)
What this study did
NCT02275481 · Sumitomo Pharma America, Inc.
2014-11 – 2016-09-14 · Chronic Obstructive Pulmonary Disease (COPD)
What this study did
NCT05506865 · National Institute of Respiratory Diseases, Mexico
2012-09 – 2016-07 · COPD
What this study did
NCT01727024 · Novartis Pharmaceuticals
2013-04 – 2015-11 · Chronic Obstructive Pulmonary Disease (COPD)
What this study did
NCT02473237 · National Institute of Respiratory Diseases, Mexico
2013-04 – 2015-08 · COPD
What this study did
NCT02039050 · University of Dundee
2014-02 – 2015-07 · Pulmonary Disease, Chronic Obstructive
What this study did
NCT01437748 · University of Milan
2011-08 – 2014-09 · Healthy, COPD
What this study did
NCT01715311 · Novartis Pharmaceuticals
2012-11 – 2013-09 · Chronic Obstructive Pulmonary Disease (COPD)
What this study did
NCT00424528 · Sumitomo Pharma America, Inc.
2006-12 – 2007-10 · Chronic Obstructive Pulmonary Disease, Bronchitis, Emphysema
What this study did
Studied as part of a combination product (1)

Studies of a fixed-dose combination that contains this drug. The combination is the product under test, so these are that product's evidence rather than this one's; the link is kept because the drug really was administered.

Phase 4 (1)
Asthma
NCT02682862 · University of Dundee
2016-07-11 – 2019-05-22 · Asthma
What this study did
Appears in other studies (10)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 3 (5)
Chronic Obstructive Pulmonary Disease
NCT03976713 · Henan University of Traditional Chinese Medicine
2019-06 – 2020-12 · Chronic Obstructive Pulmonary Disease
What this study did
NCT00846586 · Novartis Pharmaceuticals
2009-03 – 2010-03 · Chronic Obstructive Pulmonary Disease (COPD)
What this study did
NCT00877383 · Novartis Pharmaceuticals
2009-04 – 2010-02 · Chronic Obstructive Pulmonary Disease (COPD)
What this study did
Phase 4 (4)
Chronic Obstructive Pulmonary Disease
NCT02853123 · Boehringer Ingelheim
2016-09-22 – 2017-08-14 · Pulmonary Disease, Chronic Obstructive
What this study did
NCT00783250 · IRCCS Azienda Ospedaliero-Universitaria di Bologna
2008-09 – 2012-07 · Chronic Obstructive Pulmonary Disease
What this study did
NCT01465906 · Shanghai Zhongshan Hospital
2010-11 – 2011-11 · Chronic Obstructive Pulmonary Disease
What this study did
NCT01124422 · GlaxoSmithKline
2010-07-19 – 2011-05-02 · Pulmonary Disease, Chronic Obstructive
What this study did
Early phase / not applicable (1)
Chronic Obstructive Pulmonary Disease
NCT03083067 · Peking University First Hospital
2017-03-20 – 2022-03-16 · COPD Exacerbation, Air Pollution
What this study did

Competitive landscape

This mechanism is crowded: 10 other tracked programmes target it, none of them ahead of this one.

This drug's own stage for Chronic Obstructive Pulmonary Disease: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Tiotropium Bromide: this drugApprovedSmall moleculeMuscarinic acetylcholine receptor (M3)Partial signal
NCT02172287: Primary 1, trough (predose morning) FEV1 change at 6 months vs placebo: tiotropium +0.14 L, salmeterol +0.09 L (tiotropium vs salmeterol p<0.01), met. Primary 2, TDI focal score at 6 months: tiotropium +1.02 units vs placebo (p=0.01), met; salmeterol +0.24 units, not significant.
Aclidinium Bromide (Tudorza Pressair)ApprovedSmall moleculeMuscarinic acetylcholine receptor (M3)Partial signal
NCT03022097: Change from baseline in morning pre-dose (trough) FEV1 at Week 24, aclidinium bromide 400 μg vs placebo: LS mean difference 0.134 L (p<0.001); AB 400 μg 0.050 L vs placebo -0.084 L.
NCT00891462: Change From Baseline in Morning Pre-dose Forced Expiratory Volume in 1 Second (FEV1) (Change from Baseline to 12 weeks): Aclidinium Bromide, 200µg 0.062 L (Standard Error 0.015) | Aclidinium Bromide, 400µg 0.099 L (Standard Error 0.015) vs Placebo -0.025 L (Standard Error 0.015)
Aclidinium Bromide / Formoterol Fumarate (Duaklir Pressair)
ApprovedUS marketing discontinued
Small moleculeMuscarinic acetylcholine receptor (M3), Beta-2 adrenergic receptorPartial signal
NCT03022097: Change From Baseline in 1-hour Morning Post Forced Expiratory Volume in 1 Second (FEV1) (Week 24, 1-hour morning post-dose): AB/FF 400/12 μg 0.248 Litres (Standard Error 0.013) vs AB 400 μg 0.156 Litres (Standard Error 0.013) | FF 12 μg 0.138 Litres (Standard Error 0.013) | Placebo -0.05 Litres (Standard Error 0.013)
NCT02796677: Week 24, AB/FF 400/12 ug: 1-hour post-dose FEV1 vs aclidinium 400 ug +0.084 L (95% CI 0.051 to 0.117), p<0.0001; trough FEV1 vs formoterol 12 ug +0.055 L (95% CI 0.023 to 0.088), p=0.0009. Monotherapy primary: aclidinium vs tiotropium trough FEV1 +0.007 L (95% CI -0.021 to 0.035), non-inferior at the -50 mL margin (CT.gov posted results).
Budesonide / Formoterol Fumarate (SYMBICORT)ApprovedCombinationGlucocorticoid receptor; Beta-2 adrenergic receptornot yet gradedNo reviewed efficacy summary in this indication
Budesonide / Glycopyrrolate / Formoterol Fumarate (Breztri Aerosphere)ApprovedSmall moleculeGlucocorticoid receptor; Muscarinic M3; Beta-2 adrenergicReliable signal
NCT02465567: Rate of moderate/severe COPD exacerbations: PT010 (the trial's investigational triple therapy) reduced the rate by 24% vs glycopyrronium/formoterol fumarate (PT003) (p<0.001), and by 13% vs budesonide/formoterol fumarate (PT009) (p=0.003)
NCT02497001: Primary 1, FEV1 AUC0-4 at week 24, BGF MDI vs BFF MDI: LS mean difference 116 mL (95% CI 80 to 152; p<0.0001), met. Primary 2, change from baseline in morning pre-dose trough FEV1 at week 24, BGF MDI vs GFF MDI: 13 mL (95% CI -9 to 36; p=0.2375), missed. Separate Europe/Canada analysis over 24 weeks: FEV1 AUC0-4 vs BFF MDI +104 mL (95% CI 77 to 131; p<0.0001) and vs BUD/FORM DPI +91 mL (p<0.0001); trough FEV1 vs GFF MDI +22 mL (95% CI 4 to 39; p=0.0139), all met.
Dupilumab (Dupixent)ApprovedMonoclonal antibodyIL-4R-alphaPartial signal
NCT04456673: Annualized Rate of Moderate or Severe Chronic Obstructive Pulmonary Disease (COPD) Exacerbations Over the 52-week Treatment Period (Baseline (Day 1) to Week 52): Placebo 1.295 Exacerbation per participant-year (95% CI 1.048 to 1.6) | Dupilumab 300 mg q2w 0.859 Exacerbation per participant-year (95% CI 0.699 to 1.057)
NCT03930732: Annualized Rate of Moderate or Severe Chronic Obstructive Pulmonary Disease (COPD) Exacerbations Over the 52-Week Treatment Period (Baseline (Day 1) to Week 52): Placebo 1.01 exacerbation per participant-year (95% CI 0.931 to 1.301) | Dupilumab 300 mg q2w 0.776 exacerbation per participant-year (95% CI 0.645 to 0.934)
Ensifentrine (Ohtuvayre)ApprovedSmall moleculePDE3/PDE4Reliable signal
NCT05743075: Placebo-corrected change from baseline in FEV1 AUC0-12h at Week 12: +110 mL for ensifentrine (p<0.0001)
NCT04535986: Least Square (LS) Mean Change From Baseline in Average Forced Expiratory Volume in 1 Second (FEV1) Area Under the Curve Over 12 Hours (AUC0-12h) at Week 12 (Baseline (pre-dose on Day 1) and Week 12): Ensifentrine 0.0611 liters (Standard Error 0.01825) vs Placebo -0.0256 liters (Standard Error 0.0195)
Fluticasone Furoate / Umeclidinium / Vilanterol (Trelegy Ellipta)ApprovedSmall moleculeMuscarinic acetylcholine receptor (M3), Beta-2 adrenergic receptor, Glucocorticoid receptor, Glucocorticoid receptor / Beta-2 adrenergic receptor / Muscarinic M3 receptor (ICS/LABA/LAMA triple combination)Reliable signal
NCT02164513: Annual rate of on-treatment moderate/severe exacerbations: FF/UMEC/VI 0.91/yr vs FF/VI 1.07/yr (rate ratio 0.85, 95% CI 0.80-0.90, 15% reduction, p<0.001) vs UMEC/VI 1.21/yr (rate ratio 0.75, 95% CI 0.70-0.81, 25% reduction, p<0.001)
NCT02345161: Co-primary 1, trough FEV1 change to week 24 (ITT): +142 mL with FF/UMEC/VI vs -29 mL with budesonide/formoterol (LS mean difference 171 mL, 95% CI 148 to 194; P<0.001), met. Co-primary 2, SGRQ total score change to week 24 (ITT): -6.6 vs -4.3 units (LS mean difference -2.2, 95% CI -3.5 to -1.0; P<0.001), met. Supportive week-52 analyses in the extension subset: FEV1 difference 179 mL (95% CI 131 to 226; P<0.001); SGRQ difference -2.7 (95% CI -5.5 to 0.2; P=0.065), not significant.
Fluticasone Furoate / Vilanterol (Breo Ellipta)ApprovedSmall moleculeBeta-2 adrenergic receptor, Glucocorticoid receptor, Glucocorticoid receptor / Beta-2 adrenergic receptorPartial signal
NCT01313676: Number of Participants With Death (Both on and Off Treatment) Due to Any Cause, Time up to or on the Pre-determined Common End Date (From the date of randomization until date of death due to any cause (average of 2 study years)): Placebo — Dead: 275 Participants; Alive: 3832 Participants; Unknown: 4 Participants | Fluticasone Furoate 100 µg — Dead: 251 Participants; Alive: 3884 Participants; Unknown: 0 Participants | Vilanterol 25 µg — Dead: 265 Participants; Alive: 3853 Participants; Unknown: 0 Participants | Fluticasone Furoate/Vilanterol 100/25 µg — Dead: 246 Participants; Alive: 3874 Participants; Unknown: 1 Participants missed
Fluticasone Propionate / Salmeterol (Advair Diskus)ApprovedSmall moleculeGlucocorticoid receptor / Beta-2 adrenergic receptornot yet gradedNo reviewed efficacy summary in this indication
Glycopyrrolate / Formoterol Fumarate (Bevespi Aerosphere)ApprovedSmall moleculeMuscarinic acetylcholine receptor (M3), Beta-2 adrenergic receptorWeak signalFeatured results are non-efficacy only in this race
IpratropiumApprovedSmall moleculeMuscarinic acetylcholine receptor (M3)not yet gradedNo reviewed efficacy summary in this indication
Ipratropium / AlbuterolApprovedSmall moleculeMuscarinic M3 receptor / Beta-2 adrenergic receptor (combination)not yet gradedNo reviewed efficacy summary in this indication
Mepolizumab (Nucala)ApprovedMonoclonal antibodyIL-5, Interleukin-5 (IL-5), ligand-neutralizingPartial signal
NCT04133909: Annualized Rate of Moderate or Severe Exacerbations (Up to Week 104): Mepolizumab 100 mg 0.8 Exacerbations per year (95% CI 0.7 to 0.91) | Placebo 1.01 Exacerbations per year (95% CI 0.89 to 1.15)
OlodaterolApprovedSmall moleculeBeta-2 adrenergic receptorReliable signal
NCT00782210: FEV1 AUC0-3h response at Day 85 (Week 12), difference from placebo: olodaterol 5 mcg +0.172 L (SE 0.019), P<0.0001; olodaterol 10 mcg +0.176 L (SE 0.019), P<0.0001 (study 1222.11, n=624).
NCT00796653: Week 24, olodaterol 5 and 10 ug vs placebo: FEV1 AUC0-3h +0.129 and +0.154 L (both p<0.0001); trough FEV1 +0.053 L (p=0.0055) and +0.069 L (p=0.0003); TDI focal score in this study +0.402 (p=0.1999) and +0.419 (p=0.1818), not significant; TDI in the combined analysis +0.509 (p=0.0270) and +0.525 (p=0.0203) (CT.gov posted results).
Olodaterol / Tiotropium BromideApprovedSmall moleculeMuscarinic acetylcholine receptor (M3), Beta-2 adrenergic receptornot yet gradedNo reviewed efficacy summary in this indication
Revefenacin (Yupelri)ApprovedSmall moleculeMuscarinic receptors (antagonist)Reliable signal
NCT05046795: Trough FEV1 on Day 85 (Baseline and Day 85): Revefenacin Inhalation Solution 175 mcg QD. 55.12 mL (Standard Error 23.974) vs Placebo Inhalation Solution QD. -95.78 mL (Standard Error 24.504)
NCT02459080: Study 0126: trough FEV1 change at day 85 vs placebo +79 mL with revefenacin 88 µg (p=0.0003) and +146 mL with revefenacin 175 µg (p<0.0001).
Roflumilast (Daliresp)ApprovedSmall moleculePDE4not yet gradedNo reviewed efficacy summary in this indication
Salmeterol (DISKUS)ApprovedSmall moleculeBeta-2 adrenergic receptornot yet gradedNo reviewed efficacy summary in this indication
Umeclidinium (Incruse Ellipta)ApprovedSmall moleculeMuscarinic acetylcholine receptor (M3)Reliable signal
NCT02184611: Change from baseline in trough FEV1 at Day 169 (primary endpoint): UMEC 62.5 mcg vs placebo, LS mean treatment difference 154 mL (95% CI 113, 194; p<0.001)
NCT01387230: Change From Baseline (BL) in Trough Forced Expiratory Volume in One Second (FEV1) on Day 85 (Baseline and Day 85): Placebo -0.007 Liters (Standard Error 0.028) | UMEC 62.5 µg 0.12 Liters (Standard Error 0.0257) | UMEC 125 µg 0.145 Liters (Standard Error 0.0268)
Umeclidinium / VilanterolApprovedSmall moleculeMuscarinic acetylcholine receptor (M3), Beta-2 adrenergic receptorReliable signal
NCT01777334: Change From Baseline (BL) in Trough Forced Expiratory Volume in One Second (FEV1) on Day 169 (Week 24) (Baseline and Day 169): UMEC/VI 62.5/25 µg 0.205 Liters (Standard Error 0.0114) vs TIO 18 µg 0.093 Liters (Standard Error 0.0115)
NCT01716520: Change From Baseline (BL) in Weighted Mean (WM) 0-6 Hour Forced Expiratory Volume in One Second (FEV1) Obtained Post-dose at Day 14 of Each Treatment Period (TP) by Response Type (Baseline and Day 14 of each treatment period (up to study day 83)): UMEC/VI 62.5/25 µg — Responder to UMEC, n=90, 90, 88: 0.337 Liters (Standard Error 0.0166); Responder to VI, n=99, 102, 100: 0.331 Liters (Standard Error 0.0148); Responder to Neither, n=36, 37, 36: 0.13 Liters (Standard Error 0.0243) vs UMEC 62.5 µg — Responder to UMEC, n=90, 90, 88: 0.216 Liters (Standard Error 0.0166); Responder to VI, n=99, 102, 100: 0.189 Liters (Standard Error 0.015); Responder to Neither, n=36, 37, 36: 0.077 Liters (Standard Error 0.0243) | VI 25 µg — Responder to UMEC, n=90, 90, 88: 0.201 Liters (Standard Error 0.0167); Responder to VI, n=99, 102, 100: 0.233 Liters (Standard Error 0.0147); Responder to Neither, n=36, 37, 36: 0.057 Liters (Standard Error 0.024)
AstegolimabPhase 3Monoclonal antibodyST2 (IL1RL1)Partial signal
NCT05595642: ARNASA (NCT05595642), primary endpoint annualized COPD exacerbation rate (AER) at 52 weeks: astegolimab showed a numerical 14.5% reduction vs placebo, not statistically significant missed
NCT05037929: Annualized COPD exacerbation rate reduced by a statistically significant 15.4% vs placebo at 52 weeks with every-two-weeks dosing
Beclomethasone Dipropionate / Formoterol FumaratePhase 3Small moleculeGlucocorticoid receptor; β2-adrenergic receptornot yet gradedNo reviewed efficacy summary in this indication
Beclomethasone Dipropionate / Formoterol Fumarate / Glycopyrrolate (Trimbow)Phase 3Small moleculeGlucocorticoid receptor / Beta-2 adrenergic receptor / Muscarinic M3 receptor (ICS/LABA/LAMA triple combination)Reliable signalNo reviewed efficacy summary in this indication
DepemokimabPhase 3Monoclonal antibodyIL-5not yet gradedNo reviewed efficacy summary in this indication
FelcorekibartPhase 3Monoclonal antibodyTSLPnot yet gradedNo reviewed efficacy summary in this indication
HSK39004Phase 3Small moleculePhosphodiesterase 3 and Phosphodiesterase 4 (PDE3/PDE4)not yet gradedNo reviewed efficacy summary in this indication
LunsekimigPhase 3Antibody-derived scaffoldTSLP + IL-13not yet gradedNo reviewed efficacy summary in this indication
REGEND001Phase 3Cell therapyAirway epithelial regeneration (autologous basal cells)Partial signalNo reviewed efficacy summary in this indication
Tezepelumab (Tezspire)Phase 3Monoclonal antibodyTSLP, Thymic stromal lymphopoietin (TSLP), ligand-neutralizingnot yet gradedNo reviewed efficacy summary in this indication
TilrekimigPhase 3Multispecific antibodyIL-4/IL-13/TSLPnot yet gradedNo reviewed efficacy summary in this indication
TozorakimabPhase 3Monoclonal antibodyIL-33Partial signal
NCT06040086: Primary endpoint met: statistically significant reduction in the annualised rate of moderate-to-severe COPD exacerbations in former smokers and the overall population (MIRANDA, AstraZeneca, 2026-04-20).
NCT05158387: Primary endpoint met: tozorakimab reduced the annualised rate of moderate-to-severe COPD exacerbations vs placebo in former smokers and the overall population (TITANIA, 2026-03-27).
TQC3721Phase 3Small moleculePDE3/PDE4Partial signal
NCT06527144: Primary endpoint, change in peak FEV1 at week 4 vs placebo: 3 mg +100 mL (95% CI 41 to 159; P = .0011); 6 mg +147 mL (95% CI 93 to 201; P < .0001) (PACER-II, CHEST 2026).
StapokibartPhase 2/3Monoclonal antibodyIL-4R-alphanot yet gradedNo reviewed efficacy summary in this indication
9MW1911Phase 2Monoclonal antibodyIL-33/ST2, ST2 (IL1RL1)Weak signalFeatured results are safety only in this race
AlvelestatPhase 2Small moleculeNeutrophil elastasePartial signal
NCT03636347: Blood neutrophil elastase activity reduced from baseline: -83.5% (SD 56.4) at alvelestat 120mg (p=0.023) and -93.3% (SD 41.0) at 240mg (p<0.001); both doses significant vs placebo (p<0.01 and p<0.001 respectively).
AZD6793Phase 2Small moleculeIRAK4not yet gradedNo reviewed efficacy summary in this indication
BrenipatidePhase 2PeptideGLP-1/GIP receptor (dual)not yet gradedNo reviewed efficacy summary in this indication
CM512Phase 2Multispecific antibodyTSLP + IL-13not yet gradedNo reviewed efficacy summary in this indication
DexpramipexolePhase 2Small moleculeEosinophil maturation/survival (mitochondrial)not yet gradedNo reviewed efficacy summary in this indication
GlasmacinalPhase 2Small moleculeAirway epithelial barrier integrityPartial signal
NCT05516316: Primary endpoint (BALF IL-8 after inhaled LPS challenge, 375 mg EP395 daily for 3 weeks vs placebo) not met. BALF IL-6, TNF-alpha, MIP-1alpha, MIP-1beta and MCP-1 were lower and IL-33, IL-8, IL-1beta, neutrophil elastase and myeloperoxidase higher with EP395 (none statistically significant). Serum SP-D rose with EP395 (mean 148.8 to 183.0 ng/mL at 24 h, p=0.0007) but not with placebo. missed
HRS-9821Phase 2Small moleculePDE3/PDE4Weak signalNo reviewed efficacy summary in this indication
OcankitugPhase 2Monoclonal antibodyTSLPnot yet gradedNo reviewed efficacy summary in this indication
PBF-680Phase 2—Adenosine A1 receptornot yet gradedNo reviewed efficacy summary in this indication
PegtarazimodPhase 2PeptideComplement C1q / neutrophil effectors (myeloperoxidase, NETosis)not yet gradedNo reviewed efficacy summary in this indication
RademikibartPhase 2Monoclonal antibodyIL-4R-alphanot yet gradedNo reviewed efficacy summary in this indication
RC1416Phase 2Multispecific antibodyIL-4 / IL-5 / IL-13not yet gradedNo reviewed efficacy summary in this indication
RSS0343Phase 2Small molecule—not yet gradedNo reviewed efficacy summary in this indication
SolizmestrocelPhase 2Cell therapyRegenerative/anti-inflammatory (MSC)Weak signalNo reviewed efficacy summary in this indication
VerekitugPhase 2Monoclonal antibodyTSLP receptornot yet gradedNo reviewed efficacy summary in this indication
WIN378Phase 2Monoclonal antibodyTSLPnot yet gradedNo reviewed efficacy summary in this indication
XKH001Phase 2Monoclonal antibodyIL-25not yet gradedNo reviewed efficacy summary in this indication
KIT2014Phase 1/2PeptidePDE3/PDE4not yet gradedNo reviewed efficacy summary in this indication
APG808
Phase 1(overall)
Monoclonal antibodyIL-4R-alphanot yet gradedNo reviewed efficacy summary in this indication
BBT002Phase 1Multispecific antibodyIL-4Ralpha / IL-5not yet gradedNo reviewed efficacy summary in this indication
FrevecitinibPhase 1Small moleculeJAK1/2/3/TYK2Weak signalNo reviewed efficacy summary in this indication
GDC-6988Phase 1Small moleculeTMEM16A (Anoctamin-1) calcium-activated chloride channelnot yet gradedNo reviewed efficacy summary in this indication
GSK3862995Phase 1Monoclonal antibodyIL-33not yet gradedNo reviewed efficacy summary in this indication
PUR1800Phase 1Small moleculeNarrow-spectrum kinase (p38/Syk-family)not yet gradedNo reviewed efficacy summary in this indication
REGEND007Phase 1Cell therapyAirway basal layer stem cellsnot yet gradedNo reviewed efficacy summary in this indication
Ensifentrine / Glycopyrrolate
—(overall)
Small molecule—not yet gradedNo reviewed efficacy summary in this indication
GSK6759821
—(overall)
RNA / oligonucleotide—not yet gradedNo reviewed efficacy summary in this indication
RG6527
—(overall)
Undisclosed—not yet gradedNo reviewed efficacy summary in this indication
ItepekimabDiscontinuedMonoclonal antibodyIL-33Partial signal
NCT04701983: Annualized rate of moderate/severe AECOPD, reduction vs placebo at Week 52: 27% (every-2-week dosing arm), statistically significant primary endpoint met
NCT04751487: AERIFY-2 (NCT04751487), annualized rate of moderate/severe AECOPD exacerbations vs placebo at Week 52 (the primary-endpoint timepoint): 2% reduction with itepekimab every-2-weeks, 12% reduction with itepekimab every-4-weeks; neither reached statistical significance missed
NavafenterolDiscontinued—Muscarinic receptors and beta-2 adrenergic receptors, Muscarinic receptors (M1-M3) and beta-2 adrenergic receptorReliable signalNo reviewed efficacy summary in this indication

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Tiotropium bromide to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
January 2027 (1)
Phase 4AsthmaNot yet recruiting
Est. primary completion 2027-01 · NCT06679465 · CT.gov ↗
What to watch
2029 (1)
May 2029 (1)
Phase 4Bronchial Obstruction, Premature BirthNot yet recruiting
Est. primary completion 2029-05-01 · NCT07827859 · CT.gov ↗
What to watch

See the full readout calendar ↗